TetraGenetics offers a platform that generates recombinant human ion channels and transmembrane proteins such as G protein-coupled receptors. The acquisition will allow AbCellera to integrate TetraGenetics' biotechnology into its drug discovery efforts, it said.

Financial details of the acquisition were not disclosed.

Tachyon, AbCellera to develop novel cancer antibody therapeutic
Tachyon Therapeutics and antibody discovery company AbCellera are teaming up to develop a first-in-class therapeutic antibody targeting the secreted extracellular...

AbCellera, Empirico use advanced computation to discover novel antibodies
AbCellera has entered into a strategic, multitarget collaboration with Empirico to discover novel therapeutic antibodies.

AbCellera acquires Trianni for $90M
Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's...

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...

AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.